Marksans Pharma arm bags UKMHRA marketing authorization for Rasagiline Relonchem, Olmesartan tablets
Mumbai: Marksans Pharma has announced that its wholly-owned subsidiary Relonchem Limited has received Marketing Authorization from UKMHRA for Rasagiline Relonchem 1 mg Tablets, Olmesartan 10 mg Film-coated Tablets, Olmesartan 20 mg Film-coated Tablets, Olmesartan 40 mg Film-coated Tablets.
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Anti- diabetic, Pain Management, Cough & Cold, Gastroenterological and Anti - allergies. The company is marketing these products globally.
Read also: Marksans Pharma arm Relonchem bags UK MHRA marketing nod for oral solution to treat epilepsy
